CLINICAL EXAMPLES & IMAGING LITERATURE
Read the case. Check the coverage.
144 of 145 cards contain clinical imaging examples. 105 have at least three different source patients. 145 have a condition-specific imaging paper.
The aim is three clinical examples and at least one imaging paper for each condition. Different views or follow-up examinations of one patient count as one case. One original figure may contain multiple separately identified patients. Shared pattern examples retain their original exposure and do not establish a new drug association. Reused figures are unmodified and have source and licence credits.
Rows state remaining gaps. A condition-specific paper can discuss the syndrome or pattern without establishing a particular drug's causality; related-context literature is labelled separately. Histopathology, plots and teaching diagrams are not counted as clinical imaging cases. Clinical review remains pending.
| Condition | Clinical examples | Imaging literature | Scope & remaining gaps |
|---|---|---|---|
| Immune-mediated colitisGastrointestinal | 3 patients 3 figures | 2 condition-specific paper(s)
| |
| Methotrexate stroke-like neurotoxicityBrain & nervous system | 3 patients 3 figures | 1 condition-specific paper(s)
| |
| Checkpoint-related pneumonitisLungs | 4 patients 3 figures | 2 condition-specific paper(s)
| Four different ICI-pneumonitis patients in three figures: two on nivolumab and two on pembrolizumab. The pembrolizumab cases are class-pattern examples with their original exposure retained. |
| Acute gastrointestinal graft-versus-host diseaseGastrointestinal | 4 patients 4 figures | 1 condition-specific paper(s)
| |
| ICI myocarditis: a normal CMR does not exclude itHeart | 3 patients 3 figures | 3 condition-specific paper(s)
| Three different ICI-associated myocardial-injury cases. DOTATOC-PET/CT illustrates an investigational evaluation of a clinically suspected case; it is not independent proof of myocarditis. |
| Osimertinib-associated ILD / pneumonitisLungs | 6 patients 3 figures | 1 condition-specific paper(s)
| Clinical examples may illustrate the same pneumonitis pattern under another named exposure. They do not establish toxicity from this card's drug. Imaging alone cannot distinguish drug injury from infection or progression. |
| Hepatic sinusoidal obstruction after transplantationLiver & biliary | 3 patients 3 figures | 1 condition-specific paper(s)
| Three licensed SOS morphology cases are shown under their original chemotherapy exposure; no exposure-matched HCT SOS scan was selected. Do not count these as HCT cases. |
| Checkpoint-associated encephalitisBrain & nervous system | 3 patients 2 figures | 1 condition-specific paper(s)
| Three distinct patients: two in the original composite and one separate normal-MRI clinical case. Normal MRI must not be labeled a positive encephalitis finding. |
| Bone flare during abiraterone therapyBone | 1 patients 1 figures | 2 condition-specific paper(s)
| One licensed scintigraphic-flare patient under capecitabine is pattern-only and explicitly not abiraterone. Exact abiraterone-flare imaging paper found, but unrestricted original patient images not verified; three cases not reached. |
| Bone loss during aromatase inhibition: assess fractures separatelyBone | 3 patients 3 figures | 2 condition-specific paper(s)
| Three independent generic fracture cases, all pattern-only. No CT/MRI appearance proves osteoporosis or establishes aromatase-inhibitor/apalutamide/enzalutamide causality; no agent-matched fracture case selected. |
| Fractures during apalutamide-containing treatmentBone | 3 patients 3 figures | 1 condition-specific paper(s)
| Three independent generic fracture cases, all pattern-only. No CT/MRI appearance proves osteoporosis or establishes aromatase-inhibitor/apalutamide/enzalutamide causality; no agent-matched fracture case selected. |
| Fractures during enzalutamide-containing treatmentBone | 3 patients 3 figures | 1 condition-specific paper(s)
| Three independent generic fracture cases, all pattern-only. No CT/MRI appearance proves osteoporosis or establishes aromatase-inhibitor/apalutamide/enzalutamide causality; no agent-matched fracture case selected. |
| Medication-related osteonecrosis of the jawBone | 3 patients 3 figures | 1 condition-specific paper(s)
| |
| 5-FU encephalopathy / leukoencephalopathyBrain & nervous system | 3 patients 3 figures | 1 condition-specific paper(s)
| |
| CNS fungal infection during ibrutinib exposureBrain & nervous system | 3 patients 3 figures | 1 condition-specific paper(s)
| |
| Capecitabine-associated leukoencephalopathyBrain & nervous system | 3 patients 3 figures | 1 condition-specific paper(s)
| Two capecitabine-exposed cases plus one same-syndrome fluorouracil pattern example; three exact-capecitabine cases not verified. One capecitabine case has bevacizumab co-exposure and vasogenic edema. |
| Cerebral venous thrombosis with pegaspargaseBrain & nervous system | 3 patients 3 figures | 2 condition-specific paper(s)
| Two PEG-asparaginase-exposed cases; the third is a CVT pattern example from a non-oncology context. |
| Checkpoint-associated aseptic meningitisBrain & nervous system | 1 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Cyclosporine-associated PRES in transplant recipientsBrain & nervous system | 8 patients 4 figures | 2 condition-specific paper(s)
| Five distinct cyclosporine/HSCT cases are explicitly identified in one full composite, plus separate bevacizumab and pazopanib cases. EEG panels do not add cases. |
| Delayed fludarabine neurotoxicityBrain & nervous system | 6 patients 5 figures | 2 condition-specific paper(s)
| Adds three fludarabine-exposed patients in two figures: one source-attributed fludarabine case and two regimen-associated toxic leukoencephalopathy cases. Existing MTX/FU/capecitabine examples remain broader toxic-white-matter patterns with different exposure/course, not evidence of delayed fludarabine causality. |
| Delayed movement/neurocognitive toxicity after cilta-celBrain & nervous system | 1 patients 1 figures | 2 condition-specific paper(s)
| One eligible cilta-cel movement-disorder imaging case verified; three distinct cases not achieved. Additional cohort figures require source-patient mapping before integration. Do not count two PET dates as two cases or substitute acute ICANS images for this delayed syndrome. |
| Elranatamab-associated ICANSBrain & nervous system | 4 patients 4 figures | 2 condition-specific paper(s)
| One exact elranatamab case plus two other-exposure ICANS patterns. Elranatamab MRI demonstrates chronic hemorrhagic residue, not a new ICANS lesion. |
| Glofitamab-associated neurological toxicity / ICANSBrain & nervous system | 3 patients 3 figures | 1 condition-specific paper(s)
| Three distinct syndrome examples; exact product not verified for this card. Talquetamab is a bispecific-antibody case; the other cases are CAR-T (one axicabtagene, one product unspecified). MRI findings are nonspecific. |
| High-dose cytarabine cerebellar toxicityBrain & nervous system | 2 patients 2 figures | 3 condition-specific paper(s)
| One new patient plus the existing PMC8447975 patient yields two radiologically illustrated patients. Third case not filled. PMC5437478 has no imaging figures; PMC12711252 includes a clinical examination video rather than a reusable radiologic figure. PET is not a specific or routine diagnostic signature. |
| ICANS after CAR-T: a normal MRI does not exclude itBrain & nervous system | 4 patients 5 figures | 1 condition-specific paper(s)
| Two CAR-T cases plus one talquetamab same-ICANS pattern example. The latter is not a CAR-T product case. One CAR-T MRI is largely unrevealing. |
| ICANS after brexucabtagene autoleucelBrain & nervous system | 2 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| ICANS after ciltacabtagene autoleucelBrain & nervous system | 3 patients 3 figures | 1 condition-specific paper(s)
| Three distinct syndrome examples; exact product not verified for this card. Talquetamab is a bispecific-antibody case; the other cases are CAR-T (one axicabtagene, one product unspecified). MRI findings are nonspecific. |
| Ifosfamide-associated encephalopathyBrain & nervous system | 3 patients 3 figures | 4 condition-specific paper(s)
| Three distinct ifosfamide-exposed patients are illustrated. Two have normal structural imaging and one has uncommon reversible abnormalities. A normal scan does not exclude this clinical syndrome; no unique diagnostic imaging signature is established. |
| Leukoencephalopathy reported during blinatumomabBrain & nervous system | 3 patients 3 figures | 1 condition-specific paper(s)
| Dedicated blinatumomab MRI article identified but text/figures inaccessible. No eligible blinatumomab clinical figure verified. Three broader toxic leukoencephalopathy pattern examples have different exposures and courses; they do not establish the blinatumomab phenotype or clinical syndrome. |
| Neurological toxicity after idecabtagene vicleucelBrain & nervous system | 3 patients 3 figures | 1 condition-specific paper(s)
| Three distinct syndrome examples; exact product not verified for this card. Talquetamab is a bispecific-antibody case; the other cases are CAR-T (one axicabtagene, one product unspecified). MRI findings are nonspecific. |
| Neurological toxicity after lisocabtagene maraleucelBrain & nervous system | 3 patients 3 figures | 1 condition-specific paper(s)
| Three distinct syndrome examples; exact product not verified for this card. Talquetamab is a bispecific-antibody case; the other cases are CAR-T (one axicabtagene, one product unspecified). MRI findings are nonspecific. |
| PML in a rituximab-exposed patientBrain & nervous system | 3 patients 3 figures | 2 condition-specific paper(s)
| Two rituximab-exposed cases with different underlying diseases/co-exposures; the third is lymphoma-associated PML without verified rituximab exposure. |
| PRES during bevacizumab therapyBrain & nervous system | 8 patients 4 figures | 2 condition-specific paper(s)
| Only the bevacizumab figure matches this exposure; cyclosporine and pazopanib figures are PRES pattern examples. |
| PRES during pazopanib treatmentBrain & nervous system | 8 patients 4 figures | 2 condition-specific paper(s)
| Only the pazopanib figure matches this exposure; the other figures are PRES pattern examples. |
| PRES reported during bortezomibBrain & nervous system | 5 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| PRES reported with enzalutamideBrain & nervous system | 8 patients 4 figures | 2 condition-specific paper(s)
| No eligible enzalutamide figure verified; all selected figures are same-syndrome PRES examples from other exposures. |
| Tacrolimus-associated PRES after transplantationBrain & nervous system | 8 patients 4 figures | 1 condition-specific paper(s)
| Tacrolimus case is renal transplantation, not HSCT; the other figures are drug-mismatched PRES pattern examples. |
| Tarlatamab-associated ICANS in lung-cancer therapyBrain & nervous system | 3 patients 3 figures | 2 condition-specific paper(s)
| Three distinct syndrome examples; exact product not verified for this card. Talquetamab is a bispecific-antibody case; the other cases are CAR-T (one axicabtagene, one product unspecified). MRI findings are nonspecific. The exact tarlatamab paper shows metastatic lesions, so that figure was not selected as an ICANS lesion. |
| Teclistamab-associated neurological toxicity / ICANSBrain & nervous system | 3 patients 3 figures | 1 condition-specific paper(s)
| Three distinct syndrome examples; exact product not verified for this card. Talquetamab is a bispecific-antibody case; the other cases are CAR-T (one axicabtagene, one product unspecified). MRI findings are nonspecific. |
| Checkpoint-associated adrenalitisEndocrine | 2 patients 2 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Checkpoint-associated hypophysitisEndocrine | 3 patients 3 figures | 1 condition-specific paper(s)
| |
| Checkpoint-associated thyroiditisEndocrine | 4 patients 2 figures | 1 condition-specific paper(s)
| Four distinct patients across two figures; three are explicitly identified within the CT composite. Serial scans/panels do not add cases. |
| Belantamab mafodotin: microcyst-like epithelial keratopathyEyes | 3 patients 3 figures | 2 condition-specific paper(s)
| Three distinct belantamab-exposed patients in three original figures; ophthalmic clinical imaging, not orbital MRI. Noncommercial/ND figure conditions are recorded. |
| Checkpoint-associated orbital myositisEyes | 1 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Mirvetuximab-associated corneal epithelial toxicityEyes | 2 patients 2 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Retinal pigment epithelial detachment on trametinibEyes | 3 patients 3 figures | 2 condition-specific paper(s)
| Three trametinib/dabrafenib-exposed cases; phenotypes vary. One case has concomitant uveitis/vitritis and is not pure MEK-associated retinopathy. |
| Bowel perforation / fistula on bevacizumabGastrointestinal | 3 patients 3 figures | 2 condition-specific paper(s)
| |
| Capecitabine-associated ileitisGastrointestinal | 3 patients 3 figures | 2 condition-specific paper(s)
| |
| Docetaxel-associated enterocolitisGastrointestinal | 3 patients 3 figures | 1 condition-specific paper(s)
| Exact docetaxel CT case paper found, but unrestricted reuse was not established. Three checkpoint-inhibitor colitis patients illustrate nonspecific colitis morphology only, with original exposure preserved; they are not docetaxel toxicity cases. |
| Idelalisib-associated colitisGastrointestinal | 3 patients 3 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Imatinib response beyond tumour sizeGastrointestinal | 4 patients 4 figures | 2 condition-specific paper(s)
| Cross-publication patient overlap cannot be excluded where source ages/identifiers are absent; maintain per-source patient IDs. Selected examples show density, metabolism and surgical-anatomy changes, not a single universal rule. |
| Neutropenic enterocolitis after chemotherapyGastrointestinal | 3 patients 3 figures | 2 condition-specific paper(s)
| |
| Palbociclib-associated apoptotic colopathyGastrointestinal | 1 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Pegaspargase-associated pancreatitisGastrointestinal | 3 patients 3 figures | 2 condition-specific paper(s)
| No exposure-matched pegaspargase image with an unrestricted license was selected. Three pancreatitis patients are pattern/class examples: L-asparaginase, pembrolizumab and ipilimumab, each labelled by original exposure. |
| Vincristine-associated ileus / pseudo-obstructionGastrointestinal | 1 patients 1 figures | 2 condition-specific paper(s)
| One exposure-matched licensed patient selected. Radiograph/CT panels and repeated scans do not supply three independent cases. |
| Cardiac dysfunction during carfilzomibHeart | 3 patients 3 figures | 2 condition-specific paper(s)
| Three independent imaging patients available; pattern-only examples retain their original trastuzumab/combination-regimen exposure where this card names another drug. A ventricular phenotype does not identify the responsible treatment. |
| Checkpoint-associated pericarditis / pericardial effusionHeart | 1 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Cyclophosphamide-associated myocardial / pericardial injuryHeart | 3 patients 3 figures | 1 condition-specific paper(s)
| One exact cyclophosphamide/post-HCT case plus two different ICI myocarditis pattern cases. The latter illustrate myocardial injury only; they do not supply cyclophosphamide causation or hemorrhage-specific evidence. |
| Doxorubicin-associated cardiomyopathyHeart | 3 patients 3 figures | 2 condition-specific paper(s)
| Three independent imaging patients available; pattern-only examples retain their original trastuzumab/combination-regimen exposure where this card names another drug. A ventricular phenotype does not identify the responsible treatment. |
| Fluorouracil-associated cardiac injuryHeart | 3 patients 3 figures | 3 condition-specific paper(s)
| Three different exact-exposure clinical cases; two figures depict LV dysfunction and one documents coronary differential assessment. The third is not a third myocardial-pattern image. |
| Left ventricular dysfunction on trametinibHeart | 3 patients 3 figures | 1 condition-specific paper(s)
| Three independent imaging patients available; pattern-only examples retain their original trastuzumab/combination-regimen exposure where this card names another drug. A ventricular phenotype does not identify the responsible treatment. |
| Pericardial effusion reported during selpercatinibHeart | 1 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Pulmonary hypertension reported during carfilzomibHeart | 3 patients 3 figures | 2 condition-specific paper(s)
| Three different PH-pattern patients under non-carfilzomib etiologies. Matched carfilzomib clinical imaging reports identified are NC/ND and excluded from reuse; drug causality is not transferred. |
| Sunitinib-associated LV dysfunctionHeart | 3 patients 3 figures | 1 condition-specific paper(s)
| Three independent imaging patients available; pattern-only examples retain their original trastuzumab/combination-regimen exposure where this card names another drug. A ventricular phenotype does not identify the responsible treatment. |
| Trastuzumab-associated cardiac dysfunctionHeart | 3 patients 3 figures | 2 condition-specific paper(s)
| Three independent imaging patients available; pattern-only examples retain their original trastuzumab/combination-regimen exposure where this card names another drug. A ventricular phenotype does not identify the responsible treatment. |
| Cisplatin-associated renal injuryKidneys | 3 patients 3 figures | 1 condition-specific paper(s)
| |
| Gemcitabine-associated thrombotic microangiopathyKidneys | 1 patients 1 figures | 2 condition-specific paper(s)
| One licensed HUS renal-ultrasound patient is labelled STEC-associated and pattern-only. No gemcitabine/mitomycin-exposed radiologic TMA case was verified. The source does not validate a drug-specific diagnostic pattern; three cases not reached. Renal-biopsy histology is not counted as imaging. |
| ICI-related nephritis: imaging cluesKidneys | 3 patients 3 figures | 2 condition-specific paper(s)
| One ICI-matched licensed patient plus two explicitly labelled chemotherapy-associated interstitial-nephritis morphology cases. Three ICI-exposed patients with reusable images were not verified. |
| Renal toxicity during Lu-DOTATATE: limited imaging specificityKidneys | 0 patients 0 figures | 2 condition-specific paper(s)
| Imaging-method and nephrotoxicity-prediction papers are linked. The available figures are functional/dosimetry plots or tumour-burden images, not clinical diagnostic scans of renal toxicity; they are not counted as complication cases. No specific diagnostic structural signature is asserted, and three suitable clinical imaging cases remain unavailable. |
| Systemic mitomycin-associated HUS / TMAKidneys | 1 patients 1 figures | 1 condition-specific paper(s)
| One licensed HUS renal-ultrasound patient is labelled STEC-associated and pattern-only. No gemcitabine/mitomycin-exposed radiologic TMA case was verified. The source does not validate a drug-specific diagnostic pattern; three cases not reached. Renal-biopsy histology is not counted as imaging. |
| Checkpoint-associated cholecystitisLiver & biliary | 1 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| HBV reactivation after rituximabLiver & biliary | 1 patients 1 figures | 1 condition-specific paper(s)
| No rituximab-associated HBV-reactivation scan with verified unrestricted rights was found. The licensed hepatitis-A image is morphology only and must never be called an HBV/rituximab case. |
| Hepatic SOS / VOD after inotuzumabLiver & biliary | 3 patients 3 figures | 2 condition-specific paper(s)
| No inotuzumab-matched licensed scan selected. Reusable SOS examples retain oxaliplatin/S-1 or FOLFOX exposure and count as condition morphology only. |
| ICI-associated cholangitisLiver & biliary | 5 patients 3 figures | 1 condition-specific paper(s)
| |
| Immune-mediated hepatitisLiver & biliary | 3 patients 3 figures | 2 condition-specific paper(s)
| |
| Irinotecan-associated fatty liver / steatohepatitisLiver & biliary | 3 patients 3 figures | 2 condition-specific paper(s)
| |
| Oxaliplatin-associated sinusoidal liver injuryLiver & biliary | 3 patients 4 figures | 2 condition-specific paper(s)
| |
| Portal hypertension / NRH on T-DM1Liver & biliary | 1 patients 2 figures | 1 condition-specific paper(s)
| Two selected CT figures are one patient, not two cases. No three independent unrestricted T-DM1 patients verified. |
| SOS / VOD after gemtuzumab ozogamicinLiver & biliary | 4 patients 4 figures | 2 condition-specific paper(s)
| One gemtuzumab-exposed angiographic case, plus chemotherapy-SOS morphology cases under explicitly different exposures. No three gemtuzumab CT/MRI cases verified. |
| Abemaciclib-associated ILD / pneumonitisLungs | 7 patients 4 figures | 3 condition-specific paper(s)
| Clinical examples may illustrate the same pneumonitis pattern under another named exposure. They do not establish toxicity from this card's drug. Imaging alone cannot distinguish drug injury from infection or progression. |
| Alectinib-associated ILD / pneumonitisLungs | 6 patients 3 figures | 1 condition-specific paper(s)
| Clinical examples may illustrate the same pneumonitis pattern under another named exposure. They do not establish toxicity from this card's drug. Imaging alone cannot distinguish drug injury from infection or progression. |
| Amivantamab-associated lung injury / pneumonitisLungs | 6 patients 3 figures | 2 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Bleomycin pneumonitis / fibrosisLungs | 3 patients 3 figures | 1 condition-specific paper(s)
| Three independent clinical pattern examples are available under other named treatments; matched busulfan/carmustine/melphalan examples with cleared CC BY rights were not verified. Pattern similarity does not transfer drug causation. |
| Bronchiolitis obliterans syndrome after allogeneic HCTLungs | 4 patients 3 figures | 2 condition-specific paper(s)
| Three BOS-labelled patients in two original figures; captions call these autologous HCT and include coexisting PPFE/NTM. They illustrate BOS morphology, not verified allogeneic-GVHD causality. The exact allogeneic-HCT CT study is supplied separately. |
| Capmatinib-associated lung injury / pneumonitisLungs | 5 patients 2 figures | 2 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Carmustine-associated pulmonary fibrosisLungs | 3 patients 3 figures | 1 condition-specific paper(s)
| Three independent clinical pattern examples are available under other named treatments; matched busulfan/carmustine/melphalan examples with cleared CC BY rights were not verified. Pattern similarity does not transfer drug causation. |
| Cetuximab-associated lung injury / pneumonitisLungs | 5 patients 2 figures | 2 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Crizotinib-associated lung injuryLungs | 6 patients 3 figures | 1 condition-specific paper(s)
| Clinical examples may illustrate the same pneumonitis pattern under another named exposure. They do not establish toxicity from this card's drug. Imaging alone cannot distinguish drug injury from infection or progression. |
| Datopotamab deruxtecan-associated ILD / pneumonitisLungs | 4 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Delayed lung injury after busulfanLungs | 3 patients 3 figures | 1 condition-specific paper(s)
| Three independent clinical pattern examples are available under other named treatments; matched busulfan/carmustine/melphalan examples with cleared CC BY rights were not verified. Pattern similarity does not transfer drug causation. |
| Diffuse alveolar injury after HCT: consider IPS only after exclusionsLungs | 2 patients 2 figures | 2 condition-specific paper(s)
| Two independent exact IPS cases verified. A third cleared exact IPS case was not verified; PERDS, hemorrhage and infection were not relabelled as IPS to fill the target. |
| Early pulmonary events on brigatinibLungs | 6 patients 3 figures | 2 condition-specific paper(s)
| Source-matched EOPE imaging literature supplied. Displayed figures are drug-ILD morphology examples under abemaciclib, sirolimus and paclitaxel, not three brigatinib EOPE patients; EOPE has a distinct clinical/time-course context. |
| Enfortumab vedotin-associated pneumonitisLungs | 6 patients 3 figures | 1 condition-specific paper(s)
| Clinical examples may illustrate the same pneumonitis pattern under another named exposure. They do not establish toxicity from this card's drug. Imaging alone cannot distinguish drug injury from infection or progression. |
| Erlotinib-associated ILD / pneumonitisLungs | 6 patients 3 figures | 1 condition-specific paper(s)
| Clinical examples may illustrate the same pneumonitis pattern under another named exposure. They do not establish toxicity from this card's drug. Imaging alone cannot distinguish drug injury from infection or progression. |
| Everolimus-related pneumonitisLungs | 6 patients 3 figures | 1 condition-specific paper(s)
| Clinical examples may illustrate the same pneumonitis pattern under another named exposure. They do not establish toxicity from this card's drug. Imaging alone cannot distinguish drug injury from infection or progression. |
| Gefitinib-associated ILD / pneumonitisLungs | 6 patients 3 figures | 1 condition-specific paper(s)
| Clinical examples may illustrate the same pneumonitis pattern under another named exposure. They do not establish toxicity from this card's drug. Imaging alone cannot distinguish drug injury from infection or progression. |
| ILD / pneumonitis reported with apalutamideLungs | 6 patients 3 figures | 1 condition-specific paper(s)
| Clinical examples may illustrate the same pneumonitis pattern under another named exposure. They do not establish toxicity from this card's drug. Imaging alone cannot distinguish drug injury from infection or progression. |
| Immune-mediated pneumonitis across checkpoint therapiesLungs | 3 patients 2 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Lenalidomide-associated lung injury / pneumonitisLungs | 5 patients 2 figures | 2 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Melphalan-associated pneumonitis / fibrosisLungs | 3 patients 3 figures | 1 condition-specific paper(s)
| Three independent clinical pattern examples are available under other named treatments; matched busulfan/carmustine/melphalan examples with cleared CC BY rights were not verified. Pattern similarity does not transfer drug causation. |
| Olaparib-associated ILD / pneumonitisLungs | 9 patients 6 figures | 1 condition-specific paper(s)
| Clinical examples may illustrate the same pneumonitis pattern under another named exposure. They do not establish toxicity from this card's drug. Imaging alone cannot distinguish drug injury from infection or progression. |
| Organising pneumonia after breast radiotherapyLungs | 1 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Paclitaxel-associated pneumonitisLungs | 6 patients 3 figures | 2 condition-specific paper(s)
| Clinical examples may illustrate the same pneumonitis pattern under another named exposure. They do not establish toxicity from this card's drug. Imaging alone cannot distinguish drug injury from infection or progression. |
| Palbociclib-associated ILD / pneumonitisLungs | 6 patients 3 figures | 1 condition-specific paper(s)
| Clinical examples may illustrate the same pneumonitis pattern under another named exposure. They do not establish toxicity from this card's drug. Imaging alone cannot distinguish drug injury from infection or progression. |
| Pemetrexed-associated interstitial pneumonitisLungs | 7 patients 4 figures | 1 condition-specific paper(s)
| Clinical examples may illustrate the same pneumonitis pattern under another named exposure. They do not establish toxicity from this card's drug. Imaging alone cannot distinguish drug injury from infection or progression. |
| Pleural effusion during dasatinib therapyLungs | 3 patients 3 figures | 1 condition-specific paper(s)
| Three separately numbered dasatinib-exposed patients; before/after panels remain grouped within each patient. |
| Pleural effusions and thoracic changes during CAR-T CRSLungs | 3 patients 3 figures | 1 condition-specific paper(s)
| Three different patients illustrate pleural-effusion morphology, all from a dasatinib series. No three cleared exact CAR-T/CRS thoracic cases verified. The condition-specific CAR-T imaging paper is provided; images alone cannot diagnose CRS. |
| Pneumocystis pneumonia during temozolomide therapyLungs | 3 patients 3 figures | 2 condition-specific paper(s)
| Three independent PJP patients with original CC BY CT figures; none is verified as temozolomide-exposed. The matched temozolomide case (PMC5568882) is CC BY-NC-ND and excluded from image reuse. |
| Pneumonitis during disitamab vedotin plus toripalimabLungs | 1 patients 1 figures | 1 condition-specific paper(s)
| One exact combination-context CT patient verified. Seven serial panels are one case; no three-case claim and no disitamab-monotherapy causality. |
| Pomalidomide-associated lung injury / pneumonitisLungs | 6 patients 3 figures | 2 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Pulmonary invasive mould infection in the transplant settingLungs | 3 patients 2 figures | 2 condition-specific paper(s)
| Three different invasive-mould patients in two original figures: post-HCT Aspergillus and Mucor plus one IPA comparison-study patient. The third patient's transplant/drug exposure is not established. |
| Radiation-recall pneumonitis after systemic therapyLungs | 1 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Ribociclib-associated ILD / pneumonitisLungs | 6 patients 3 figures | 1 condition-specific paper(s)
| Clinical examples may illustrate the same pneumonitis pattern under another named exposure. They do not establish toxicity from this card's drug. Imaging alone cannot distinguish drug injury from infection or progression. |
| Sirolimus-associated pneumonitisLungs | 6 patients 3 figures | 2 condition-specific paper(s)
| Clinical examples may illustrate the same pneumonitis pattern under another named exposure. They do not establish toxicity from this card's drug. Imaging alone cannot distinguish drug injury from infection or progression. |
| Sotorasib-associated lung injury / pneumonitisLungs | 5 patients 2 figures | 2 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| T-DXd–associated ILD / pneumonitisLungs | 6 patients 3 figures | 1 condition-specific paper(s)
| |
| Telisotuzumab vedotin-associated ILD / pneumonitisLungs | 4 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Temsirolimus-related pneumonitisLungs | 6 patients 3 figures | 1 condition-specific paper(s)
| Clinical examples may illustrate the same pneumonitis pattern under another named exposure. They do not establish toxicity from this card's drug. Imaging alone cannot distinguish drug injury from infection or progression. |
| Transient pulmonary opacities on osimertinibLungs | 2 patients 2 figures | 2 condition-specific paper(s)
| Two distinct TAPO patients verified, only one on osimertinib. The original osimertinib report (PMC5353353) is not CC BY in official metadata. Figure 2/3 patient overlap in PMC9968596 is not resolved, so panels are not counted as additional cases. |
| Diffuse marrow & splenic FDG uptakeMarrow | 3 patients 3 figures | 2 condition-specific paper(s)
| Two pegfilgrastim patients plus one explicitly lenograstim pattern example. Only the first source illustrates heterogeneous regeneration; focal sternal uptake is an atypical pattern. |
| MDS / AML risk during olaparib exposureMarrow | 2 patients 2 figures | 2 condition-specific paper(s)
| Two general MDS patients are illustrated with original T1-weighted MRI figures. Neither is an olaparib-exposed case; no olaparib-specific diagnostic imaging signature is established. Three suitable distinct patients have not yet been verified. |
| Marrow FDG activation after filgrastimMarrow | 3 patients 3 figures | 2 condition-specific paper(s)
| No unrestricted exact-filgrastim patient image selected. Three labelled G-CSF pattern patients are two pegfilgrastim and one lenograstim; no timing transfer between products. |
| Aldesleukin-associated capillary leakMultiple organs | 1 patients 1 figures | 1 condition-specific paper(s)
| One conservative unidentifiable figure example; no three independent patients can be established from its panels. Product not named. Cardiac injury and vascular leak should not be conflated. |
| Apparent progression on immunotherapyMultiple organs | 3 patients 3 figures | 3 condition-specific paper(s)
| |
| Chylous effusions during selpercatinibMultiple organs | 1 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Docetaxel-associated fluid retentionMultiple organs | 1 patients 1 figures | 2 condition-specific paper(s)
| Exact-condition CT case paper verified, but its images are NC-ND. A licensed imatinib-associated pleural-effusion CT is explicitly pattern-only. No three docetaxel-exposed unrestricted cases selected. |
| Enasidenib-associated differentiation syndromeMultiple organs | 2 patients 2 figures | 3 condition-specific paper(s)
| Two independent enasidenib-exposed patients; one more needed for target three. Whole mixed skin/CXR figure retained unchanged, only B is relevant radiologic content. |
| Fistula / organ perforation on lenvatinibMultiple organs | 2 patients 2 figures | 3 condition-specific paper(s)
| Two licensed clinical contexts selected; the second image shows an associated abscess, not the tract. Three unrestricted direct fistula/perforation scan cases were not verified. |
| Imatinib-associated fluid retentionMultiple organs | 3 patients 3 figures | 2 condition-specific paper(s)
| One unrestricted exposure-matched CT case. Other radiographs in the same report repeat that patient; no three distinct unrestricted cases verified. |
| Ivosidenib differentiation syndromeMultiple organs | 2 patients 2 figures | 3 condition-specific paper(s)
| Zero verified reusable exposure-matched ivosidenib figures. Two same-condition examples from enasidenib are explicitly pattern-only. Exact ivosidenib report has no checked reusable figure/grant; no causality transfer. |
| Loncastuximab tesirine: effusions and edemaMultiple organs | 3 patients 3 figures | 1 condition-specific paper(s)
| Three independent pleural-effusion pattern cases from dasatinib. Exact loncastuximab-associated clinical images not verified. No pericardial/ascites image is supplied under a false matched exposure. |
| Mixed PSMA-PET response during Lu-PSMA therapyMultiple organs | 1 patients 1 figures | 1 condition-specific paper(s)
| One conservative patient example. Baseline/interim and manual/segmented views are not four independent cases; PSMA-617 versus I&T is not individually identified in the figure. No three independent licensed examples verified. |
| Splenic rupture reported after filgrastimMultiple organs | 1 patients 1 figures | 2 condition-specific paper(s)
| One class-context licensed rupture patient, with G-CSF formulation unspecified. Lenograstim, pegfilgrastim and splenic-infarction cases were not relabelled as exact filgrastim rupture. |
| Checkpoint-associated inflammatory arthritisMuscles & joints | 1 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Checkpoint-associated myositisMuscles & joints | 1 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Sarcoid-like thoracic lymphadenopathyNodes | 4 patients 4 figures | 1 condition-specific paper(s)
| |
| ICI-associated pancreatic inflammationPancreas | 4 patients 4 figures | 2 condition-specific paper(s)
| |
| Pancreatitis reported during brentuximab vedotinPancreas | 1 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Tamoxifen-associated endometrial changesPelvis & reproductive | 3 patients 3 figures | 3 condition-specific paper(s)
| Three source patients/examples, including one unidentified ultrasound-study figure. Ultrasound Figures1/2 are not assumed independent. Imaging does not justify asymptomatic screening or establish histologic malignancy. |
| Cyclophosphamide-associated hemorrhagic cystitisUrinary tract | 2 patients 2 figures | 1 condition-specific paper(s)
| One cyclophosphamide-matched and one explicitly BK/post-HCT morphology patient. Three alkylator-specific unrestricted cases not verified. |
| Haemorrhagic cystitis after HCTUrinary tract | 2 patients 2 figures | 2 condition-specific paper(s)
| One exact BK/HCT patient plus one cyclophosphamide pattern-only patient. Ultrasound cohort images are restricted and their individual BK status is not established by captions. |
| Ifosfamide-associated hemorrhagic cystitisUrinary tract | 2 patients 2 figures | 1 condition-specific paper(s)
| No unrestricted ifosfamide-exposed cystitis scan verified. Cyclophosphamide and BK-HCT scans are labelled morphology-only; no ifosfamide causality is inferred. |
| Aortic wall thickening after G-CSFVessels | 6 patients 1 figures | 1 condition-specific paper(s)
| |
| Nilotinib-associated arterial occlusive diseaseVessels | 1 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |
| Ponatinib-associated arterial occlusive diseaseVessels | 1 patients 1 figures | 1 condition-specific paper(s)
| Original source figures are preferred. Additional distinct clinical cases remain a target; repeated views of one patient count once. |